{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:25:58Z","timestamp":1791653158719,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Horizon 2020 Framework Program of the European Union","award":["667224"],"award-info":[{"award-number":["667224"]}]},{"name":"Deutsche Forschungsgemeinschaft and the Open Access Publishing Fund of the University of T\u00fcbingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12887-019-1566-8","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T08:26:09Z","timestamp":1561623969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III)"],"prefix":"10.1186","volume":"19","author":[{"name":"for the ALBINO Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Maiwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim V.","family":"Annink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"R\u00fcdiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon J. N. L.","family":"Benders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"van Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Allegaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Naulaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Bassler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Kleberma\u00df-Schrehof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximo","family":"Vento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hercilia","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Stiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Cattarossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjo","family":"Mets\u00e4ranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampsa","family":"Vanhatalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Mazela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuuli","family":"Metsvaht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannique","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5066-0857","authenticated-orcid":false,"given":"Axel R.","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"issue":"6","key":"1566_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.earlhumdev.2010.05.010","volume":"86","author":"JJ Kurinczuk","year":"2010","unstructured":"Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev. 2010;86(6):329\u201338.","journal-title":"Early Hum Dev"},{"issue":"2","key":"1566_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1315788","volume":"371","author":"D Azzopardi","year":"2014","unstructured":"Azzopardi D, Strohm B, Marlow N, Brocklehurst P, Deierl A, Eddama O, et al. Effects of hypothermia for perinatal asphyxia on childhood outcomes. N Engl J Med. 2014;371(2):140\u20139.","journal-title":"N Engl J Med"},{"issue":"14","key":"1566_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa0900854","volume":"361","author":"DV Azzopardi","year":"2009","unstructured":"Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009;361(14):1349\u201358.","journal-title":"N Engl J Med"},{"key":"1566_CR4","doi-asserted-by":"publisher","first-page":"c363","DOI":"10.1136\/bmj.c363","volume":"340","author":"AD Edwards","year":"2010","unstructured":"Edwards AD, Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, Levene M, et al. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ. 2010;340:c363.","journal-title":"BMJ"},{"issue":"8","key":"1566_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","volume":"46","author":"RO Day","year":"2007","unstructured":"Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623\u201344.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1566_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1056\/NEJM198501173120305","volume":"312","author":"JM McCord","year":"1985","unstructured":"McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312(3):159\u201363.","journal-title":"N Engl J Med"},{"issue":"3","key":"1566_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.semperi.2015.12.003","volume":"40","author":"F Bel","year":"2016","unstructured":"Bel F, Groenendaal F. Drugs for neuroprotection after birth asphyxia: pharmacologic adjuncts to hypothermia. Semin Perinatol. 2016;40(3):152\u20139.","journal-title":"Semin Perinatol"},{"issue":"38","key":"1566_CR8","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.2174\/1381612823666170918123307","volume":"23","author":"KV Annink","year":"2017","unstructured":"Annink KV, Franz AR, Derks JB, Rudiger M, Bel FV, Benders M. Allopurinol: old drug, new indication in neonates? Curr Pharm Des. 2017;23(38):5935\u201342.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"1566_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0304-3940(98)00303-6","volume":"248","author":"M Shadid","year":"1998","unstructured":"Shadid M, Buonocore G, Groenendaal F, Moison R, Ferrali M, Berger HM, et al. Effect of deferoxamine and allopurinol on non-protein-bound iron concentrations in plasma and cortical brain tissue of newborn lambs following hypoxia-ischemia. Neurosci Lett. 1998;248(1):5\u20138.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1566_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0014-5793(87)81458-8","volume":"213","author":"PC Moorhouse","year":"1987","unstructured":"Moorhouse PC, Grootveld M, Halliwell B, Quinlan JG, Gutteridge JM. Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS Lett. 1987;213(1):23\u20138.","journal-title":"FEBS Lett"},{"key":"1566_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.brainres.2005.11.061","volume":"1073-1074","author":"PJ Marro","year":"2006","unstructured":"Marro PJ, Mishra OP, Delivoria-Papadopoulos M. Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res. 2006;1073-1074:444\u201350.","journal-title":"Brain Res"},{"issue":"3","key":"1566_CR12","doi-asserted-by":"publisher","first-page":"F163","DOI":"10.1136\/adc.2005.086652","volume":"91","author":"MJ Benders","year":"2006","unstructured":"Benders MJ, Bos AF, Rademaker CM, Rijken M, Torrance HL, Groenendaal F, et al. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Arch Dis Child Fetal Neonatal Ed. 2006;91(3):F163\u20135.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"2","key":"1566_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1542\/peds.101.2.185","volume":"101","author":"F Van Bel","year":"1998","unstructured":"Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics. 1998;101(2):185\u201393.","journal-title":"Pediatrics."},{"issue":"3","key":"1566_CR14","doi-asserted-by":"publisher","first-page":"F162","DOI":"10.1136\/archdischild-2011-300356","volume":"97","author":"JJ Kaandorp","year":"2012","unstructured":"Kaandorp JJ, van Bel F, Veen S, Derks JB, Groenendaal F, Rijken M, et al. Long-term neuroprotective effects of allopurinol after moderate perinatal asphyxia: follow-up of two randomised controlled trials. Arch Dis Child Fetal Neonatal Ed. 2012;97(3):F162\u20136.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"1","key":"1566_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pediatrneurol.2006.08.005","volume":"36","author":"T Gunes","year":"2007","unstructured":"Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I. Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns. Pediatr Neurol. 2007;36(1):17\u201324.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"1566_CR16","doi-asserted-by":"publisher","first-page":"F216","DOI":"10.1136\/archdischild-2014-306769","volume":"100","author":"JJ Kaandorp","year":"2015","unstructured":"Kaandorp JJ, Benders MJ, Schuit E, Rademaker CM, Oudijk MA, Porath MM, et al. Maternal allopurinol administration during suspected fetal hypoxia: a novel neuroprotective intervention? A multicentre randomised placebo controlled trial. Arch Dis Child Fetal Neonatal Ed. 2015;100(3):F216\u201323.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"1","key":"1566_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1542\/peds.2008-2228","volume":"124","author":"HL Torrance","year":"2009","unstructured":"Torrance HL, Benders MJ, Derks JB, Rademaker CM, Bos AF, Van Den Berg P, et al. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. Pediatrics. 2009;124(1):350\u20137.","journal-title":"Pediatrics."},{"key":"1566_CR18","doi-asserted-by":"publisher","unstructured":"Chaudhari T, McGuire W. Allopurinol for preventing mortality and morbidity in newborn infants with suspected hypoxic-ischaemic encephalopathy. Cochrane Database Syst Rev. 2008;(2):Cd006817. https:\/\/doi.org\/10.1002\/14651858.CD006817.pub2","DOI":"10.1002\/14651858.CD006817.pub2"},{"issue":"3","key":"1566_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/01.ftd.0000211808.74192.86","volume":"28","author":"C van Kesteren","year":"2006","unstructured":"van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, Rademaker CM. Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. Ther Drug Monit. 2006;28(3):339\u201344.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1566_CR20","doi-asserted-by":"publisher","first-page":"F27","DOI":"10.1136\/fn.73.1.F27","volume":"73","author":"GA Russell","year":"1995","unstructured":"Russell GA, Cooke RW. Randomised controlled trial of allopurinol prophylaxis in very preterm infants. Arch Dis Child Fetal Neonatal Ed. 1995;73(1):F27\u201331.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"6 Pt 1","key":"1566_CR21","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1542\/peds.94.6.820","volume":"94","author":"SP McGaurn","year":"1994","unstructured":"McGaurn SP, Davis LE, Krawczeniuk MM, Murphy JD, Jacobs ML, Norwood WI, et al. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome. Pediatrics. 1994;94(6 Pt 1):820\u20133.","journal-title":"Pediatrics."},{"issue":"1","key":"1566_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1542\/peds.108.1.61","volume":"108","author":"RR Clancy","year":"2001","unstructured":"Clancy RR, McGaurn SA, Goin JE, Hirtz DG, Norwood WI, Gaynor JW, et al. Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest. Pediatrics. 2001;108(1):61\u201370.","journal-title":"Pediatrics."},{"issue":"4","key":"1566_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1203\/00006450-199704000-00010","volume":"41","author":"PJ Marro","year":"1997","unstructured":"Marro PJ, Baumgart S, Delivoria-Papadopoulos M, Zirin S, Corcoran L, McGaurn SP, et al. Purine metabolism and inhibition of xanthine oxidase in severely hypoxic neonates going onto extracorporeal membrane oxygenation. Pediatr Res. 1997;41(4 Pt 1):513\u201320.","journal-title":"Pediatr Res"},{"issue":"6","key":"1566_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000457187","volume":"7","author":"D Boda","year":"1984","unstructured":"Boda D, Nemeth I, Hencz P, Denes K. Effect of allopurinol treatment in premature infants with idiopathic respiratory distress syndrome. Dev Pharmacol Ther. 1984;7(6):357\u201367.","journal-title":"Dev Pharmacol Ther"},{"issue":"10","key":"1566_CR25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","volume":"36","author":"SN Ramasamy","year":"2013","unstructured":"Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang N, Roberts DM, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013;36(10):953\u201380.","journal-title":"Drug Saf"},{"issue":"4","key":"1566_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","volume":"12","author":"LK Stamp","year":"2016","unstructured":"Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016;12(4):235\u201342.","journal-title":"Nat Rev Rheumatol"},{"issue":"15","key":"1566_CR27","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1056\/NEJMcps050929","volume":"353","author":"S Shankaran","year":"2005","unstructured":"Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353(15):1574\u201384.","journal-title":"N Engl J Med"},{"key":"1566_CR28","doi-asserted-by":"publisher","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053","DOI":"10.1001\/jama.2013.281053"},{"issue":"2","key":"1566_CR29","doi-asserted-by":"publisher","first-page":"F144","DOI":"10.1136\/archdischild-2013-304876","volume":"99","author":"JJ Kaandorp","year":"2014","unstructured":"Kaandorp JJ, van den Broek MP, Benders MJ, Oudijk MA, Porath MM, Bambang Oetomo S, et al. Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour. Arch Dis Child Fetal Neonatal Ed. 2014;99(2):F144\u20138.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1566_CR30","first-page":"16","volume-title":"Review of the role of mannitol in the therapy of children. 18th expert committee on the selection and use of essential medicines mannitol review (children)","author":"F Tavakkoli","year":"2011","unstructured":"Tavakkoli F. Review of the role of mannitol in the therapy of children. 18th expert committee on the selection and use of essential medicines mannitol review (children); 2011. p. 16."},{"key":"1566_CR31","unstructured":"Cadence Pharmaceuticals, Inc. - OFIRMEV\u00ae (acetaminophen) injection - Approval Label (PDF) 11\/2010 - https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022450lbl.pdf (downloaded 2019\/01\/29)."},{"key":"1566_CR32","unstructured":"Fresenius Kabi USA, LLC - acetaminophen injection, for intravenous use - approval label (PDF) 10\/2015 - https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/204767s000lbl.pdf (downloaded 2019\/01\/29)."},{"key":"1566_CR33","unstructured":"Mallinckrodt hospital products Inc. - OFIRMEV\u00ae (acetaminophen) injection - labeling-package insert (PDF) 04\/2018 - https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022450s011lbl.pdf (downloaded 2019\/01\/29)."}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-019-1566-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12887-019-1566-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-019-1566-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T02:32:04Z","timestamp":1663813924000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-019-1566-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1186\/s12887-019-1566-8","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ALBINO trial is performed in accordance with the Declaration of Helsinki and the guidelines of Good Clinical Practice (GCP). Written informed consent must be obtained by the parents or legal guardians before full participation in the study (i.e. before administration of the second dose of study medication (if indicated) and before data-entry into the database). Whether oral consent by at least one parent is obtained following short information or an approved waiver of consent is applied before administration of the first dose of study medication, depends on the approvals of the responsible national ethics committees (as detailed elsewhere). At the time of publication, the ALBINO trial is currently taking place in 10 European countries and may expand to other countries, including Poland and Portugal, once ethical approval has been obtained.Austria: Ethics: Ethikkommission Medizinische Universit\u00e4t Wien, reference no. 1731\/2017, approved with deferred consent; <i>Authority:<\/i> Bundesamt f\u00fcr Sicherheit im Gesundheitswesen, reference no. 10680185 approved conduct.Belgium: Coordinating ethical committee: Ethical Committee UZ Leuven reference no. S60224, approved with deferred consent; <i>Authority:<\/i> Federal Agency for Medicines and Health Products Brussels, reference no. FAGG\/R&D\/MMN approved conduct.Estonia: Ethics: Research Ethics Committee of the University of Tartu (UT REC), reference no. 272\/T-13, approved with deferred consent; Authority: State Agency of Medicines clinical trial, reference no. 17\u2013044 approved conduct.Finland: Ethics: Naisten, lasten ja psykiatrian eettinen toimikunta, Helsingin ja Uudenmaan sairaanhoitopiiri reference no. HUS\/1528\/2017 approved with deferred consent; <i>Authority:<\/i> Finnish Medicines Agency (FIMEA) reference no. 44\/ 2017 approved conduct.Germany: Ethics: Ethics Committee at the University Hospital Tuebingen, <i>reference no.<\/i> 703\/2016AMG1, approved with short oral consent; Authority: Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, reference no. 4041912 approved conduct.Italy: Ethics: COMITATO ETICO UNICO REGIONALE sede operative CENTRO di RIFERIMENTO ONCOLOGICO reference no. 6.1 21\/11\/2017 - ID 2167 approved with short oral consent; Authority: AIFA- Agenzia Italiana del Farmaco reference no. 97707 approved conduct.Netherlands: Ethics: The ethical committee of the University Medical Center Utrecht reference no. NL57237.041.16 <i>approved with short oral consent; Authority: Centrale Commissie Mensgebonden Onderzoek (CCMO)<\/i> reference no. NL57237.041.16 approved conduct.Norway: Ethics: REK \u2013 Regionale komiteer for medisinsk og helsefaglig forskningsetikk reference no. 2017\/800 approved with deferred consent; <i>Authority:<\/i> Norwegian Medicines Agency reference no. 17\/04729\u201311 approved conduct.Poland: Ethics: to be submitted <i>Authority:<\/i> to be submitted.Portugal: Ethics: CEIC - Comiss\u00e3o de \u00c9tica para a Investiga\u00e7\u00e3o Cl\u00ednica - Waiting for approval; Authority: INFARMED - Autoridade Nacional do Medicamento e Produtos de Sa\u00fade, I.P. - approved conduct.Spain: Ethics: Ethics Committee for Research with Medications at the Hospital Universitario y Polit\u00e9cnico de La Fe. reference no. 2016\u2013000222-19 approved with Short Oral Consent; Authority: Spanish Agency of Medicines reference no.2016\u2013000222-19 approved with Short Oral Consent.Switzerland: Ethics: Kantonale Ethikkommission Z\u00fcrich, reference no. 2017\/00961, approved with short oral consent; <i>Authority:<\/i> Swissmedic - Swiss agency for therapeutic products, reference no. 2017DR3135 approved conduct.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y. Jacobs and R. van der Vlught-Meijer are employees of ACE Pharmaceuticals, the company that holds the Dutch marketing authorization registration for Acepurin\u00ae (allopurinol 1\u2009g\/100\u2009ml) for intravenous application for treatment of gout. C. van Veldhuizen and B. Lam\u00e9ris are the former owners of ACE Pharmaceuticals. All four contributed to the development of the study protocol. All other contributors declare that they do not have competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}